PBSVOTCServices-Management Consulting ServicesFiscal year ends October 31
Pharma-Bio Serv, Inc.
Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 14, 2026
$0.48+0.08 (+20.00%)
Close on Oct 19, 2026
- Market cap
- $11.00M
- P/E (TTM)
- 48.0
- Dividend yield
- –
Pharma-Bio Serv statistics
Financials through Jul 31, 2026, price as of Oct 19, 2026, median of Services-Management Consulting Services companies for comparison
Valuation
| Measure | Pharma-Bio Serv | Industry median |
|---|---|---|
| Market Cap | $10.99M | $74.60M |
| Enterprise Value | $2.42M | $56.72M |
| PE Ratio | 48.00 | 25.83 |
| PS Ratio | 1.16 | 3.25 |
| PB Ratio | 1.05 | 3.13 |
| P/TBV Ratio | 1.05 | 8.30 |
Enterprise value
| Measure | Pharma-Bio Serv | Industry median |
|---|---|---|
| EV / Sales | 0.25 | 2.79 |
Income (trailing twelve months)
| Measure | Pharma-Bio Serv | Industry median |
|---|---|---|
| Revenue | $9.48M | $24.74M |
| Gross Profit | $3.07M | $19.54M |
| Operating Income | -$154.94K | -$55.64K |
| Pretax Income | $269.00K | $45.62K |
| Net Income | $251.53K | -$97.64K |
| EBITDA | -$97.01K | -$29.48K |
| EPS (Diluted) | $0.01 | $0.00 |
Margins
| Measure | Pharma-Bio Serv | Industry median |
|---|---|---|
| Gross Margin | 32.3% | 40.4% |
| Operating Margin | -1.63% | 0.94% |
| Pretax Margin | 2.84% | 2.64% |
| Profit Margin | 2.65% | 0.51% |
| EBITDA Margin | -1.02% | 3.48% |
| FCF Margin | -4.44% | 5.05% |
Returns
| Measure | Pharma-Bio Serv | Industry median |
|---|---|---|
| Return on Equity (ROE) | 2.25% | 0.45% |
| Return on Assets (ROA) | 2.01% | -3.47% |
| Return on Invested Capital (ROIC) | -9.44% | 2.85% |
| Return on Capital Employed (ROCE) | -1.48% | 2.03% |
Growth
| Measure | Pharma-Bio Serv | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 3.25% | 4.26% |
| Revenue Growth (3Y CAGR) | -22.6% | 2.15% |
| Revenue Growth (5Y CAGR) | -16.0% | 7.37% |
Balance sheet
| Measure | Pharma-Bio Serv | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $8.58M | $5.43M |
| Net Cash (Debt) | $8.58M | $17.62K |
| Net Cash Per Share | $0.37 | $0.00 |
| Equity (Book Value) | $10.44M | $10.50M |
| Book Value Per Share | $0.46 | $0.60 |
| Tangible Book Value | $10.44M | -$78.36K |
| Working Capital | $10.24M | $2.78M |
Financial position
| Measure | Pharma-Bio Serv | Industry median |
|---|---|---|
| Current Ratio | 11.30 | 1.26 |
| Quick Ratio | 11.06 | 0.65 |
Cash flow (trailing twelve months)
| Measure | Pharma-Bio Serv | Industry median |
|---|---|---|
| Operating Cash Flow | -$414.89K | $8.04K |
| Capital Expenditures | -$6.47K | -$8.33M |
| Free Cash Flow | -$421.36K | $11.03M |
| FCF Per Share | -$0.02 | $0.76 |
Efficiency
| Measure | Pharma-Bio Serv | Industry median |
|---|---|---|
| Asset Turnover | 0.76 | 0.83 |
| Revenue Per Employee | $49.91K | $216.23K |
| Profits Per Employee | $1.32K | -$3.19K |
| Employee Count | 190 | 123 |
Dividends and yields
| Measure | Pharma-Bio Serv | Industry median |
|---|---|---|
| Earnings Yield | 2.29% | -0.97% |
| FCF Yield | -3.83% | 3.90% |
| Buyback Yield | 0.11% | 1.36% |
| Shareholder Yield | 0.11% | 1.65% |
Shares
| Measure | Pharma-Bio Serv | Industry median |
|---|---|---|
| Shares Outstanding | 22,901,700 | 29,217,800 |
| Shares Change (YoY) | -0.12% | 0.84% |
| Shares Change (QoQ) | 0.00% | 0.00% |
| Float | 20,431,300 | 26,226,050 |
| Shares Held by Insiders | 10.8% | 4.85% |
Taxes
| Measure | Pharma-Bio Serv | Industry median |
|---|---|---|
| Income Tax | $17.47K | $1.36M |
| Effective Tax Rate | 6.50% | 23.6% |
Scores
| Measure | Pharma-Bio Serv | Industry median |
|---|---|---|
| Graham Number | $0.32 | $16.51 |
| Graham Upside | -33.3% | -50.2% |
| Altman Z-Score | 9.60 | 2.66 |
| Piotroski F-Score | 5 | 5 |
| Beneish M-Score | -2.93 | -2.75 |
Calculated by StockData from Pharma-Bio Serv's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.